The Board of Directors of UCrest wishes to announce that the Company had on 7 October 2022 signed agreement to invest and to lead the investment of Docsun Biomed Limited (“Docsun”), a holding company that owns a leading US medical technology company that has developed non-contact, non-invasive, non-intrusive vital signs and it has a subsidiary in Taiwan and India. The Company had also on 7 October 2022, signed an Exclusive Distribution Agreement (“EDA”) with Docsun where Docsun is appointed by UCrest as the exclusive distributor for the US market of the iMedic-Docsun integrated products.
Please refer to the attachment for further information.